[go: up one dir, main page]

BR0311952A - New compounds useful for treating obesity, type ii diabetes and snc disorders - Google Patents

New compounds useful for treating obesity, type ii diabetes and snc disorders

Info

Publication number
BR0311952A
BR0311952A BR0311952-1A BR0311952A BR0311952A BR 0311952 A BR0311952 A BR 0311952A BR 0311952 A BR0311952 A BR 0311952A BR 0311952 A BR0311952 A BR 0311952A
Authority
BR
Brazil
Prior art keywords
diabetes
type
compounds useful
new compounds
treating obesity
Prior art date
Application number
BR0311952-1A
Other languages
Portuguese (pt)
Inventor
Johansson
Gary
Jenmalm-Jensen
Annika
Beierlein
Katarina
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201925A external-priority patent/SE0201925D0/en
Priority claimed from SE0202181A external-priority patent/SE0202181D0/en
Priority claimed from SE0202908A external-priority patent/SE0202908D0/en
Priority claimed from SE0300357A external-priority patent/SE0300357D0/en
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of BR0311952A publication Critical patent/BR0311952A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"NOVOS COMPOSTOS úTEIS PARA O TRATAMENTO DE OBESIDADE, DIABETES TIPO II E DISTúRBIOS DO SNC". A presente invenção refere-se e compostos de fórmula geral (I) onde P é sulfona ou sulfonamida e A, B, W, X, Y e ^ R3^ são como definidos no relatório descritivo, a composições farmacêuticas compreendendo estes compostos, e ao uso dos compostos para a profilaxia e tratamento de condições médicas relativas à obesidade, diabetes do tipo II, e/ou distúrbios do SNC, para obter-se redução do peso corporal e do ganho de peso corporal."NEW USEFUL COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS". The present invention relates to and compounds of formula (I) wherein P is sulfone or sulfonamide and A, B, W, X, Y and R 3 are as defined in the specification, pharmaceutical compositions comprising these compounds, and the use of the compounds for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, and / or CNS disorders to achieve reduction in body weight and body weight gain.

BR0311952-1A 2002-06-20 2003-06-19 New compounds useful for treating obesity, type ii diabetes and snc disorders BR0311952A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
SE0201925A SE0201925D0 (en) 2002-06-20 2002-06-20 New compounds
SE0202181A SE0202181D0 (en) 2002-07-11 2002-07-11 New compounds
US40612002P 2002-08-26 2002-08-26
SE0202908A SE0202908D0 (en) 2002-10-01 2002-10-01 New compounds
US43401002P 2002-12-17 2002-12-17
SE0300357A SE0300357D0 (en) 2003-02-10 2003-02-10 New compounds
US46470103P 2003-04-23 2003-04-23
PCT/SE2003/001061 WO2004000828A1 (en) 2002-06-20 2003-06-19 New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Publications (1)

Publication Number Publication Date
BR0311952A true BR0311952A (en) 2005-04-19

Family

ID=30004107

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311952-1A BR0311952A (en) 2002-06-20 2003-06-19 New compounds useful for treating obesity, type ii diabetes and snc disorders

Country Status (13)

Country Link
EP (1) EP1513828A1 (en)
CN (1) CN1662521A (en)
AU (1) AU2003243091A1 (en)
BR (1) BR0311952A (en)
CA (1) CA2486989A1 (en)
EA (2) EA008835B1 (en)
IL (1) IL165051A0 (en)
MX (1) MXPA04012914A (en)
NO (1) NO20050294L (en)
NZ (3) NZ536600A (en)
RS (1) RS111204A (en)
SG (1) SG156524A1 (en)
WO (1) WO2004000828A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY138836A (en) 2002-03-27 2009-07-31 Glaxo Group Ltd Quinoline derivatives and their use as 5-ht6 receptor ligands
SE0301446D0 (en) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
MY141862A (en) 2003-07-22 2010-07-16 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
SE0302760D0 (en) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
SE0303480D0 (en) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
EA010298B1 (en) * 2003-12-19 2008-08-29 Биовитрум Аб (Пабл) Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-htreceptor-related disorder
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
US7745436B2 (en) * 2004-04-13 2010-06-29 Synta Pharmaceuticals Corporation Disalt inhibitors of IL-12 production
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
AR054044A1 (en) * 2005-05-23 2007-05-30 Astrazeneca Ab CHROMAN AND TETRAHYDRONAFTALENE DERIVATIVES AS RECEPTOR MODULATORS 5 - HT6; INTERMEDIARIES IN THEIR PREPARATION; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPELO IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CNS AND OBESITY DISEASES.
US7582767B2 (en) * 2005-06-17 2009-09-01 Biovitrum Ab (Publ.) Substituted sulphonamide compound and uses thereof
WO2007003961A2 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
NZ594630A (en) 2005-10-07 2013-04-26 Exelixis Inc N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
ES2359735T3 (en) 2005-11-03 2011-05-26 F. Hoffmann-La Roche Ag ARYLSULPHONYL CHROMANES AS 5-HT6 INHIBITORS.
UY30048A1 (en) 2005-12-23 2007-07-31 Astrazeneca Ab SUBSTITUTED DERIVATIVES OF THE N, 2- (1H-BENZIMIDAZOL-1-IL) ACETAMIDE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
WO2007147763A1 (en) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Arylsulfonyl naphthalene derivatives and uses thereof
EP2035370A2 (en) 2006-06-20 2009-03-18 F. Hoffmann-Roche AG Tetralin and indane derivatives and uses thereof
KR101064001B1 (en) 2006-06-20 2011-09-08 에프. 호프만-라 로슈 아게 Arylsulfonamidyl tetralin derivatives and uses thereof
TWI433839B (en) 2006-08-11 2014-04-11 Neomed Inst Novel benzimidazole derivatives 290
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US7888662B2 (en) 2008-06-20 2011-02-15 Varian Semiconductor Equipment Associates, Inc. Ion source cleaning method and apparatus
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
AR082889A1 (en) * 2011-05-09 2013-01-16 Forma Therapeutics Inc COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT
WO2015090233A1 (en) 2013-12-20 2015-06-25 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
CA2989343A1 (en) 2015-06-12 2016-12-15 Yandong Wen Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
RU2018103338A (en) 2015-07-15 2019-08-15 Аксовант Сайенсиз Гмбх Derivatives of diaryl and arylheteroarylureas for the prevention and treatment of hallucinations associated with a neurodegenerative disease
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB947606A (en) * 1961-04-10 1964-01-22 Ici Ltd N-substituted piperazines
US4808595A (en) * 1986-12-24 1989-02-28 Merck & Co., Inc. Furopyridine sulfonamides and their opthalmological compositions
DE69427289T2 (en) * 1993-03-16 2001-09-06 Pfizer Inc., New York NAPHTAL DERIVATIVES
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
DZ2376A1 (en) * 1996-12-19 2002-12-28 Smithkline Beecham Plc New sulfonamide derivatives process for their preparation and pharmaceutical compositions containing them.
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
AU1542201A (en) * 1999-11-05 2001-05-14 Nps Allelix Corp. Compounds having 5-HT6 receptor antagonist activity
CA2408156A1 (en) * 2000-05-05 2001-11-15 Millennium Pharmaceuticals, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
AU2001259707A1 (en) * 2000-06-14 2001-12-24 Warner Lambert Company 6,5-fused bicyclic heterocycles
PL361887A1 (en) * 2000-10-20 2004-10-04 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
BR0209558A (en) * 2001-05-11 2004-04-20 Biovitrum Ab New Arylsulfonamide Compounds for the Treatment of Obesity, Type II Diabetes, and Snc Disorders
EP1401813B1 (en) * 2001-06-07 2007-02-07 F. Hoffman-la Roche AG New indole derivatives with 5-ht6 receptor affinity
WO2002100822A1 (en) * 2001-06-11 2002-12-19 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes

Also Published As

Publication number Publication date
EP1513828A1 (en) 2005-03-16
NZ552283A (en) 2008-07-31
SG156524A1 (en) 2009-11-26
EA011581B1 (en) 2009-04-28
WO2004000828A1 (en) 2003-12-31
IL165051A0 (en) 2005-12-18
NZ536600A (en) 2007-08-31
CA2486989A1 (en) 2003-12-31
MXPA04012914A (en) 2005-03-31
CN1662521A (en) 2005-08-31
AU2003243091A1 (en) 2004-01-06
NO20050294L (en) 2005-02-04
RS111204A (en) 2006-12-15
EA008835B1 (en) 2007-08-31
EA200500054A1 (en) 2005-06-30
NZ552282A (en) 2008-07-31
EA200600975A1 (en) 2006-10-27

Similar Documents

Publication Publication Date Title
BR0311952A (en) New compounds useful for treating obesity, type ii diabetes and snc disorders
BRPI0409227B8 (en) "compound, pharmaceutical composition, use of a compound and process for the preparation of a compound of formula (i)"
DE60013250D1 (en) Phenylharnstoffe und phenylthioharnstoffe als orexinrezeptorantagonisten
RU2325389C2 (en) Composition and derivatives of substituted azaindoloxoacetapiperazine characterized by antiviral activity
WO2004067550A3 (en) Novel use of mifepristone and derivatives thereof as hedgehog protein signalling pathway modulators and applications of same
SE0403006D0 (en) New compounds
BR0116370A (en) Compound, pharmaceutical composition, use of a compound, and method of treating an hppar-mediated disease or condition in a patient.
BRPI0418099A (en) compounds, pharmaceutical composition, and use of a compound
ATE384058T1 (en) THIAZOLE DERIVATIVES
ATE381537T1 (en) FORMANILIDE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS
ATE385419T1 (en) DERMATOLOGICAL AND COSMETIC COMPOSITIONS CONTAINING A FURFURYL DERIVATIVE
SE0102764D0 (en) Compounds
EP2037739A4 (en) POSITIVE ALLOSTERIC EFFECTORS OF BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR
EA200600971A1 (en) APPLICATION OF SUBSTITUTED 2 - AMINOTHETRALINES FOR THE PREVENTION TREATMENT OF PARKINSON'S Disease
WO2002079169A8 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
DE60233350D1 (en) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
WO2002079149A3 (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
BR0213417A (en) Tetracycliczaindoles and indolines compounds and compositions having 5-ht activity and their uses
SE0303480D0 (en) Benzofuranes
CY1109950T1 (en) NEW PRODUCTS OF 4,4-DYPHYTHODES- (3-AMINOBUTANIUM-1-SULPHONIC) AND COMPOSITIONS CONTAINING THEM
DE602004015089D1 (en) PYRROLOIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THESE INGREDIENT COMPOSITIONS, AND THEIR USE AS NOOTROPIKA
EA200601687A1 (en) Tetrahydroisoquinoline TETRAGIDROBENZAZEPINOVYE AND DERIVATIVES (OPTIONS), pharmaceutical compositions and pharmaceutical kits, medicinal and reference instruments for the test-systems based on them, methods of treatment and prevention of diseases in which the down-regulation of a favorable or inhibiting the expression or function of IGF-1 Receptor
NO20052699L (en) 4 (phenylpiperazinylmethyl) benzamide derivatives and their use in the treatment of pain and gastrointestinal disorders.
BRPI0413684A (en) compounds, pharmaceutical composition and methods of preparation, treatment of microbial infection and extermination of microorganism and uses
TW200510354A (en) Benzoxazinone-derived sulphonamide compounds, their preparation and use as medicaments

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BIOVITRUM AB (PUBL) (SE)

Free format text: ALTERADO DE: BIOVITRUM AB

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 207/12, C07D 211/40, C07D 211/46, C07D 215/46, C07D 217/22, C07D 401/04, C07D 406/12, C07D 471/04, C07D 495/04, A61K 31/40, A61K 31/4025, A61K 31/4353, A61K 31/4465, A61K 31/4523, A61K 31/496, A61K 31/551, A61P 25/00, A61P 3/04, A61P 3/10, A61P 3/00, A61P 43/00

Ipc: C07D 401/04 (2011.01), C07D 495/04 (2011.01), C07D

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 8A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 8A ANUIDADE.